Complement C5 and Early Oxygen Kinetics during Murine Sepsis
dc.contributor.author | Valencia, Gabriel | en_US |
dc.contributor.author | Sarma, J. Vidya | en_US |
dc.contributor.author | Younger, John G. | en_US |
dc.date.accessioned | 2010-06-01T21:38:53Z | |
dc.date.available | 2010-06-01T21:38:53Z | |
dc.date.issued | 2005-04 | en_US |
dc.identifier.citation | Valencia, Gabriel; Sarma, J. Vidya; Younger, John G. (2005). "Complement C5 and Early Oxygen Kinetics during Murine Sepsis." Academic Emergency Medicine 12(4): 275-281. <http://hdl.handle.net/2027.42/74696> | en_US |
dc.identifier.issn | 1069-6563 | en_US |
dc.identifier.issn | 1553-2712 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74696 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15805316&dopt=citation | en_US |
dc.format.extent | 124959 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/octet-stream | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | © 2005 Society for Academic Emergency Medicine | en_US |
dc.subject.other | Open-circuit Calorimetry | en_US |
dc.subject.other | Oxygen Consumption | en_US |
dc.subject.other | Respiratory Exchange Ratio | en_US |
dc.subject.other | C5a, Anaphylatoxin | en_US |
dc.title | Complement C5 and Early Oxygen Kinetics during Murine Sepsis | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Emergency Medicine, University of Michigan, Ann Arbor, MI. | en_US |
dc.contributor.affiliationum | Departments of Pathology, University of Michigan, Ann Arbor, MI. | en_US |
dc.identifier.pmid | 15805316 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74696/1/j.aem.2004.10.025.pdf | |
dc.identifier.doi | 10.1197/j.aem.2004.10.025 | en_US |
dc.identifier.source | Academic Emergency Medicine | en_US |
dc.identifier.citedreference | Angus, DC, Linde-Zwirble, WT, Clermont, G, Carcillo, J, Pinksy, M. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29: 1303 – 10. | en_US |
dc.identifier.citedreference | Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001; 349: 1368 – 77. | en_US |
dc.identifier.citedreference | Moriyama S, Okamoto K, Tabira Y et al. Evaluation of oxygen consumption and resting energy expenditure in critically ill patients with systemic inflammatory response syndrome. Crit Care Med. 1999; 27: 2133 – 6. | en_US |
dc.identifier.citedreference | Siegel J, Cerra F, Coleman B et al. Physiologic and metabolic correlations in human sepsis. Surgery. 1979; 86: 163 – 93. | en_US |
dc.identifier.citedreference | Reiss M, Roos D. Differences in oxygen metabolism of phagocytosing monocytes and neutrophils. J Clin Invest. 1978; 61: 480 – 8. | en_US |
dc.identifier.citedreference | Watts JA, Kline JA. Bench to bedside: the role of mitochondrial medicine in the pathogenesis and treatment of cellular injury. Acad Emerg Med. 2003; 10: 985 – 97. | en_US |
dc.identifier.citedreference | Ebong, S, Call, D, Nemzek, J, Bolgos, G, Newcomb, D, Remick, D. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun. 1999; 67: 6603 – 10. | en_US |
dc.identifier.citedreference | Lumb AB. Nunn's Applied Respiratory Physiology. Oxford, UK: Butterworth Heinemann, 2000. | en_US |
dc.identifier.citedreference | Henderson B, Poole S, Wilson M. Bacteria and cytokines: beyond lipopolysaccharide. In: Bacteria–Cytokine Interactions in Health and Disease. Miami, FL: Portland Press, 1998, 211 – 80. | en_US |
dc.identifier.citedreference | Henderson B, Poole S, Wilson M. Lipopolysaccharides and cytokines: a tangled web. In: Bacteria–Cytokine Interactions in Health and Disease. Miami, FL: Portland Press, 1998, pp 167 – 210. | en_US |
dc.identifier.citedreference | Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med. 2003; 31 ( suppl ): S97 – S104. | en_US |
dc.identifier.citedreference | Ward PA. The darkside of C5a in sepsis. Nature Rev Immunol. 2004; 4: 133 – 42. | en_US |
dc.identifier.citedreference | Hopken, EU, Bao, L, Gerard, NP, Gerard, C. The C5a chemoattractant receptor mediates mucosal defense to infection. Nature. 1996; 383: 86 – 9. | en_US |
dc.identifier.citedreference | Younger JG, Shankar-Sinha S, Mickiewicz M et al. Murine complement interactions with Pseudomonas aeruginosa and their effects during acute pneumonia. Am J Respir Cell Mol Biol. 2003; 29: 432 – 8. | en_US |
dc.identifier.citedreference | Czermak BJ, Sarma V, Pierson CL et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999; 5: 788 – 92. | en_US |
dc.identifier.citedreference | Younger JG, Sasaki N, Delgado J et al. Systemic and lung physiological changes after intravascular activation of complement with cobra venom factor. J Appl Physiol. 2001; 90: 2289 – 95. | en_US |
dc.identifier.citedreference | Guo RF, Huber-Lang M, Wang X et al. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest. 2000; 106: 1271 – 80. | en_US |
dc.identifier.citedreference | Huber-Lang MS, Sarma JV, McGuire SR et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J. 2001; 15: 568 – 70. | en_US |
dc.identifier.citedreference | Laudes IJ, Chu JC, Sikranth S et al. Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol. 2002; 160: 1867 – 75. | en_US |
dc.identifier.citedreference | Wetsel RA, Fleischer DT, Haviland DL. Deficiency of the murine fifth complement component (C5): a 2-base pair gene deletion in a 5′-exon. J Biol Chem. 1990; 265: 2435 – 40. | en_US |
dc.identifier.citedreference | Wheat, WH, Wetsel, R, Falus, A, Tack, BF, Strunk, RC. The fifth component of complement (C5) in the mouse: analysis of the molecular basis of deficiency. J Exp Med. 1987; 165: 1442 – 7. | en_US |
dc.identifier.citedreference | Riedemann NC, Guo RF, Ne TA et al. Increased C5a receptor expression in sepsis. J Clin Invest. 2001; 110: 101 – 8. | en_US |
dc.identifier.citedreference | Younger JG, Sasaki N, Waite MD et al. Detrimental effects of complement activation in hemorrhagic shock. J Appl Physiol. 2000; 90: 441 – 6. | en_US |
dc.identifier.citedreference | Shankar-Sinha S, Valencia GA, Janes BK et al. Klebsiella pneumoniae O-antigen contributes to bacteremia and lethality during murine pneumonia. Infect Immun. 2004; 72: 1423 – 30. | en_US |
dc.identifier.citedreference | Cerquetti, MC, Sordelli, DO, Bellanti, JA, Hooke, AM. Lung defenses against Pseudomonas aeruginosa in C5-deficient mice with different genetic backgrounds. Infect Immun. 1986; 52: 853 – 7. | en_US |
dc.identifier.citedreference | Rosenberg LT, Tachibana DK. Mice deficient in C5 Progr. Allergy. 1986; 39: 169 – 91. | en_US |
dc.identifier.citedreference | Huber-Lang MS, Riedemann NC, Sarma JV et al. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J. 2002; 16: 1567 – 74. | en_US |
dc.identifier.citedreference | Verrier ED, Sherman SK, Taylor KM et al. Investigators Primo-CABG. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA. 2004; 291: 2319 – 27. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.